Bobo WV - Search Results

1

Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.

Kamali M, Pegg S, Janos JA, Bobo WV, Brody B, Gao K, Ketter TA, McElroy SL, McInnis MG, Rabideau DJ, Reilly-Harrington NA, Shelton RC, Sylvia LG, Tohen M, Nierenberg A. Kamali M, et al. Among authors: bobo wv. J Psychiatr Res. 2021 Aug;140:205-213. doi: 10.1016/j.jpsychires.2021.05.082. Epub 2021 Jun 2. J Psychiatr Res. 2021. PMID: 34118638 Free PMC article. Clinical Trial.

2

Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Bobo WV, Shelton RC. Bobo WV, et al. Neuropsychiatr Dis Treat. 2009;5:369-83. doi: 10.2147/ndt.s5819. Epub 2009 Jul 2. Neuropsychiatr Dis Treat. 2009. PMID: 19590732 Free PMC article.

3

Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.

Bobo WV, Shelton RC. Bobo WV, et al. Expert Opin Pharmacother. 2009 Sep;10(13):2145-59. doi: 10.1517/14656560903130609. Expert Opin Pharmacother. 2009. PMID: 19640209 Review.

4

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.

Bobo WV, Epstein RA, Shelton RC. Bobo WV, et al. Hum Psychopharmacol. 2010 Jan;25(1):30-6. doi: 10.1002/hup.1082. Hum Psychopharmacol. 2010. PMID: 20029794 Clinical Trial.

5

Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data.

Bobo WV, Stovall JA, Knostman M, Koestner J, Shelton RC. Bobo WV, et al. Am J Health Syst Pharm. 2010 Jan 1;67(1):27-37. doi: 10.2146/ajhp080595. Am J Health Syst Pharm. 2010. PMID: 20044366 Review.

6

Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.

Bobo WV, Shelton RC. Bobo WV, et al. Expert Rev Neurother. 2010 May;10(5):651-70. doi: 10.1586/ern.10.44. Expert Rev Neurother. 2010. PMID: 20420487 Review.

7

Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.

Bobo WV, Shelton RC. Bobo WV, et al. Expert Rev Neurother. 2010 Nov;10(11):1637-58. doi: 10.1586/ern.10.143. Expert Rev Neurother. 2010. PMID: 20977322 Review.

8

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.

Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC. Bobo WV, et al. J Affect Disord. 2011 Oct;133(3):467-76. doi: 10.1016/j.jad.2011.04.032. Epub 2011 May 23. J Affect Disord. 2011. PMID: 21601287 Free PMC article. Clinical Trial.

9

Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.

Bobo WV, Bonaccorso S, Jayathilake K, Meltzer HY. Bobo WV, et al. Psychiatry Res. 2011 Sep 30;189(2):200-7. doi: 10.1016/j.psychres.2011.07.008. Epub 2011 Jul 28. Psychiatry Res. 2011. PMID: 21802150

10

Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.

Bobo WV, Epstein RA Jr, Shelton RC. Bobo WV, et al. Ann Clin Psychiatry. 2011 Aug;23(3):193-201. Ann Clin Psychiatry. 2011. PMID: 21808751 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page